Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’ - Schöffski, Patrick; Kasper, Bernd (Annals of oncology, 2018)
Gesehen am 22.07.2020